Mucoangin Johannisbeere (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucoangin Johannisbeere, is a mucolytic presented as an oral formulation for oromucosal use. It helps to loosen and clear thick respiratory secretions in patients with bronchitis, COPD, and other upper‑respiratory tract infections.

GNH USA supplies Mucoangin Johannisbeere as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Ambroxol acts on the respiratory mucosa to improve clearance of viscous secretions in several conditions.

Acute bronchitis: reduces mucus viscosity and facilitates expectoration. Chronic bronchitis: supports long‑term mucus clearance and symptom relief. Chronic obstructive pulmonary disease (COPD): aids in managing productive cough and airway clearance. Upper respiratory tract infections: helps alleviate thick‑sputum cough associated with viral or bacterial infections.

Ambroxol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Altered taste sensation - Nausea or mild stomach upset - Diarrhea - Headache - Dizziness - Mild abdominal discomfort

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic enzyme elevations - Eosinophilic pneumonia - Bronchospasm in susceptible individuals - Hematologic abnormalities (e.g., eosinophilia)

When using Ambroxol, consider the following safety measures.

Pregnancy: consult a healthcare professional as safety data are limited. Breastfeeding: use with caution and only if clearly needed. Renal impairment: monitor renal function and adjust use if required. Asthma or reactive airway disease: observe for possible bronchospasm. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Ambroxol may interact with other medicines; assess the risk before co‑administration.

Major Interactions (Avoid): - Cytotoxic chemotherapy agents (e.g., cyclophosphamide): may increase pulmonary toxicity. - Anticholinergic drugs: can diminish mucociliary clearance benefits.

Moderate Interactions (Monitor Closely): - Antihistamines: may blunt secretory effects of Ambroxol. - Cough suppressants (e.g., dextromethorphan): may counteract expectorant action. - Beta‑blockers: may affect bronchial response in susceptible patients.